<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602316</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000581176</org_study_id>
    <secondary_id>RMH-CCR2995</secondary_id>
    <nct_id>NCT00602316</nct_id>
  </id_info>
  <brief_title>Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer</brief_title>
  <official_title>Using Magnetic Resonance Techniques to Improve the Characterisation and Localisation of Breast Cancer. A Pilot Observational Study Testing the Accuracy of Multifunctional Magnetic Resonance Techniques in Predicting the Presence, Distribution and Nature of Breast Lesions in Women With Known Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as multifunctional magnetic resonance imaging, may&#xD;
      help doctors learn the extent of disease and plan the best treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well multifunctional magnetic resonance imaging&#xD;
      works in predicting breast lesions in women undergoing mastectomy for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the accuracy of multifunctional magnetic resonance (MR) in detecting,&#xD;
           localizing, and characterizing satellite lesions in relation to an index breast tumor in&#xD;
           order to improve definition of clinical target volume after local excision.&#xD;
&#xD;
      OUTLINE: Patients receive an injection of gadolinium chelate and undergo multifunctional&#xD;
      magnetic resonance (MR) imaging, including dynamic contrast-enhanced MR, hydrogen-MR&#xD;
      spectroscopy, and diffusion-weighted MRI, of the ipsilateral breast within 4 weeks before&#xD;
      surgery. Patients undergo a mastectomy as planned. The resected specimen is photographed, and&#xD;
      a histopathological analysis is performed consisting of the size and grade (if pre-invasive&#xD;
      or invasive disease) of each satellite lesion, classification of benign satellite lesions,&#xD;
      dimensions of each lesion, distance from the edge of the index tumor to the center of each&#xD;
      satellite lesion, and the distance from the center of the surface of the nipple to the center&#xD;
      of each lesion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of magnetic resonance (MR) techniques in detecting histopathologically-identified multifocal and multicentric lesions</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closeness of agreement between MR techniques and histopathology in localizing satellite lesions relative to the index tumor</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of distribution of satellite lesions in relation to index tumor</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between histopathological characteristics and signal changes on multifunctional MR</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadolinium-chelate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-confirmed invasive ductal carcinoma of the breast&#xD;
&#xD;
          -  Unifocal disease as defined by clinical examination, mammography, and ultrasound&#xD;
&#xD;
          -  Patient must be proceeding to mastectomy&#xD;
&#xD;
          -  Hormone receptor status unknown&#xD;
&#xD;
          -  No T4d or multifocal disease (as defined on conventional imaging)&#xD;
&#xD;
          -  Index tumor â‰¤ 4 cm in diameter&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  No claustrophobia&#xD;
&#xD;
          -  No cup size of DD or greater&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior surgery to ipsilateral breast&#xD;
&#xD;
          -  No prior neoadjuvant chemotherapy&#xD;
&#xD;
          -  No prior ferromagnetic implants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Kirby</last_name>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-208-661-3392</phone>
      <email>annakirby@doctors.org.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chelating Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

